Our data suggests the landscape of hnRNPs, and specifically hnRNP L, are ALS/FTD disease modifiers, acting to limit aberrant splicing events by compensating for TDP-43 when it is depleted. This evidence concerns the gene HNRNPL and amyotrophic lateral sclerosis.